medigraphic.com
Instituto Nacional de Salud Pública

2024, Number 4

<< Back Next >>

salud publica mex 2024; 66 (4)

Mexico’s Universal Vaccination Program, challenges and proposals for improvement

Language: Spanish
References: 41
Page: 606-615
PDF size: 260.69 Kb.


ABSTRACT

Despite the efforts made by the coordinators and operators of Mexico’s Universal Vaccination Program (PVU, in Spanish), at all levels, a complex and extensive program like this always encounters barriers that are a challenge to achieving and maintaining the expected success. Every PVU requires structural, functional and financial growth that guarantees the acquisition of enough vaccines and that they reach the target person, at the right time and with quality assurance. With the objective of identifying challenges of the PVU and propose improvement actions, the Undersecretary of Prevention and Health Promotion and the National Center for Child and Adolescent Health (Censia, in Spanish) requested the National Institute of Public Health (INSP, in Spanish) and the Pan American Health Organization/World Health Organization (PAHO/WHO), office of Representation in Mexico, to convene a group of independent national and international experts, to hold a dialogue and analysis with federal and state personnel who direct and operate the PVU. This manuscript describes a summary of the topics presented, relevant elements of the discussion and general recommendations.


REFERENCES

  1. Santos JI. La vacunación en México en el marco de las “décadas de lasvacunas”: logros y desafíos. Gac Med Mex. 2014;150:180-8. Disponible en:https://www.anmm.org.mx/GMM/2014/n2/GMM_150_2014_2_180-188.pdf

  2. Secretaría de Salud. Programa de vacunación universal. Lineamientosgenerales 2023. México: Centro Nacional para la Atención de la Salud dela Infancia y Adolescentes, 2023. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/790120/LineamientosGeneralesPVU_2023.pdf

  3. Organización Panamericana de la Salud, Organización Mundial de laSalud. Evaluación internacional del programa de vacunación universalde México. México: OPS, OMS, 2015 [citado jul 1, 2024]. Disponibleen: https://www3.paho.org/hq/dmdocuments/2017/inmunizaciones-epiinternationalevaluation-mex-2014-s.pdf

  4. Fondo de las Naciones Unidas para la Infancia, Instituto Nacional deSalud Pública. Encuesta nacional de niños, niñas y mujeres 2015. Encuestade indicadores múltiples por conglomerados 2015, informe final. México:Unicef, INSP, 2016 [citado jul 1, 2024]. Disponible en: https://www.unicef.org/mexico/media/1001/file/UNICEF_ENIM2015.pdf

  5. Hernández-Ávila M, Palacio-Mejía LS, Hernández-Ávila JE, CharvelS. Vacunación en México: coberturas imprecisas y deficiencia en elseguimiento de los niños que no completan el esquema. Salud PublicaMex. 2020;62(2):215-24. https://doi.org/10.21149/10682

  6. Centro Nacional para la Salud de la Infancia y Adolescencia. Históricode coberturas de vacunación 2019-2023. Coberturas Sectoriales devacunación por entidad federativa y biológico, en niñas y niños menoresde 1 año, 1 año, 4 y 6 años de edad, 2019-2023. México: Censia, 2024[citado jul 1, 2024]. Disponible en: https://www.gob.mx/salud/censia/es/articulos/historico-de-coberturas-de-vacunacion-2019-2023?idiom=es

  7. Mongua-Rodríguez N, Delgado-Sánchez G, Ferreira-Guerrero E,Ferreyra-Reyes LD, Martínez-Hernández M, Canizales-Quintero S, etal. coberturas de vacunación en niños y adolescentes en México. SaludPublica Mex. 2023;65(supl 1):23-33. https://doi.org/10.21149/14790

  8. Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arrendondo S, Colchero MA, Gaona-Pineda EB, et al. Metodología de laEncuesta Nacional de Salud y Nutrición 2022 y planeación y diseño de laEnsanut Continua 2020-2024. Salud Publica Mex. 2022;64(5):522-9. https://doi.org/10.21149/14186

  9. Cutts FT, Hanson M. Seroepidemiology: an underused tool fordesigning and monitoring vaccination programmes in low- and middleincomecountries. Trop Med Int Health. 2016;21(9):1086-98. https://doi.org/10.1111/tmi.12737

  10. Organización Mundial de la Salud. Guidance on conductingserosurveys in support of measles and rubella elimination in the WHOEuropean Region. Dinamarca: OMS, 2013 [citado abr 20, 2024]. Disponibleen: https://iris.who.int/bitstream/handle/10665/350485/WHO-EURO-2013-4502-44265-62531-eng.pdf?sequence=1&isAllowed=y

  11. Organización Mundial de la Salud. Annex 2. Tetanus serosurveys:Vaccine-preventable diseases surveillance standards. Ginebra: OMS, 2018[citado jun 28, 2024]. Disponible en: https://www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-annex2

  12. Fondo de las Naciones Unidas para la Infancia. Encuesta de IndicadoresMúltiples por Conglomerados (MICS). Unicef, 2023 [citado jul 23, 2024].Disponible en: https://mics.unicef.org

  13. Organización Mundial de la Salud, Fondo de las Naciones Unidas parala Infancia. WHO and Unicef estimates of immunization coverage: 2023revision. OMS, Unicef, 2024 [citado jul 13, 2024]. Disponible en: https://www.who.int/publications/m/item/immunization-2024-mexico-countryprofile

  14. Minta AA, Ferrari M, Antoni S, Portnoy A, Sbarra A, Lambert B, et al.Progress toward measles elimination - Worldwide, 2000-2022. Morb MortalWkly Rep. 2023;72(46):1262-8. https://doi.org/10.15585/mmwr.mm7246a3

  15. Organización Mundial de la Salud. Measles. OMS, 2024 [citado jun 30,2024]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/measles

  16. Organización Mundial de la Salud. Poliomyelitis. OMS, 2023 [citadojun 30, 2024]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/poliomyelitis

  17. Comité Nacional para la Vigilancia Epidemiológica. Avisoepidemiológico. Circulación de otros virus respiratorios (OVR),incremento en predomino de virus sincicial respiratorio (VSR). México:Conave, 2023 [citado jul 18, 2024]. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/871841/Aviso_Epidemiol_gico_VSR_nov_2023_f.pdf

  18. Hernández-Rivas L, Pedraz T, Calvo C, San Juan I, Mellado MJ,Robustillo A. Respiratory syncytial virus outbreak during the COVID-19pandemic. How has it changed? Enferm Infecc Microbiol Clin.2023;41(6):352-55. https://doi.org/10.1016/j.eimc.2021.12.003

  19. Ministerio de Salud Argentina. Comunicación epidemiológica, SE23.Circulación de Influenza, VSR y otros virus respiratorios. Argentina:Ministerio de Salud, 2023. Disponible en: https://bancos.salud.gob.ar/sites/default/files/2023-06/comunicacion-influenza-ovr-06-2023.pdf

  20. Organización Panamericana de la Salud. Actualización regional,influenza y otros virus respiratorios. Semana Epidemiológica 43 (3 denoviembre de 2023). Washington: OPS, 2023. Disponible en: https://iris.paho.org/handle/10665.2/58450

  21. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global,regional, and national disease burden estimates of acute lower respiratoryinfections due to respiratory syncytial virus in children younger than 5years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-64.https://doi.org/10.1016/S0140-6736(22)00478-0

  22. Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós MT, et al. Effectiveness and impact of universalprophylaxis with nirsevimab in infants against hospitalisation forrespiratory syncytial virus in Galicia, Spain: initial results of a populationbasedlongitudinal study. Lancet Infect Dis. 2024;24(8):817-28. https://doi.org/10.1016/S1473-3099(24)00215-9

  23. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M,et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in olderadults. N Engl J Med. 2023;388(16):1465-77. https://doi.org/10.1056/NEJMoa2213836

  24. Guiñazú G, Dvorkin J, Mahmud S, Baral R, Pecenka C, Libster R, et al.Evaluation of the impact and cost-effectiveness of respiratory syncytialvirus prevention strategies for infants in Argentina. SSRN [preprint]. 2024.https://doi.org/10.2139/ssrn.4754920

  25. Herzog C, Van-Herck K, Van-Damme P. Hepatitis A vaccination and itsimmunological and epidemiological long-term effects – a review of theevidence. Human Vacc Immun. 2021;17(5):1496-519 https://doi.org/10.1080/21645515.2020.1819742

  26. Gentile A, Ramonet M, Ellis A, Abate H, Alonso M, Bruno M, et al.Análisis sobre la necesidad de incorporación de la vacuna contra hepatitisA en la Argentina. Arch Argent Pediatr. 2004;102(6):487-98. Disponible en:http://www.scielo.org.ar/pdf/aap/v102n6/v102n6a15.pdf

  27. Urueña A, González JE, Rearte A, Pérez-Carrega ME, Calli R, PaganiMF, et al. Single-dose universal hepatitis A immunization in one-year-oldchildren in Argentina: High prevalence of protective antibodies up to 9years after vaccination. Pediatric Infect Dis J. 2016;35(12):1339-42. https://doi.org/10.1097/INF.0000000000001322

  28. Organización Panamericana de la Salud, Organización Mundialde la Salud. Putting the brakes on hepatitis A in Argentina. Singledosevaccination strategy for infants dramatically reduces cases andhas eradicated the need for transplants due to acute liver failurein children. Buenos Aires: OPS, OMS, 2018 [citado jul 17, 2024].Disponible en: https://www.paho.org/en/stories/putting-brakeshepatitis-argentina

  29. Secretaría de Salud. Informe epidemiológico anual de vigilanciaepidemiológica de hepatitis virales. México: DGE, 2019. Disponible en:https://www.gob.mx/cms/uploads/attachment/file/574743/Informe_epidemiologico_hepatitis_virales_2019.pdf

  30. Lazcano-Ponce E, Conde-González C, Rojas R, DeAntonio R, Romano-Mazzotti L, Cervantes Y, et al. Seroprevalence of hepatitis A virus in a crosssectionalstudy in Mexico: implications for hepatitis A vaccination. HumVaccin Immunother. 2013;9(2):375-81. https://doi.org/10.4161/hv.22774

  31. López-Gatell H, García-García L, Echániz-Avilés G, Cruz-HervertP, Olamendi-Portugal M, Castañeda-Desales D, et al. Hepatitis Aseroprevalence in adolescents and young adults in Mexico: a 2012National Health and Nutrition Survey analysis. Vaccine. 2018;36(52):8094-9. https://doi.org/10.1016/j.vaccine.2018.10.037

  32. Guzman-Holst A, Luna-Casas G, Burguete-García A, Madrid-MarinaV, Cervantes-Apolinar MY, Andani A, et al. Burden of disease andassociated complications of hepatitis a in children and adults in Mexico: aretrospective database study. PLoS One. 2022;17(5):e0268469. https://doi.org/10.1371/journal.pone.0268469

  33. Gershon AA, Takahashi M, Seward JF. Varicella vaccine. En: PlotkinSA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Ámsterdam: ElsevierSaunders, 2013:836-69.

  34. Quian J, Rüttimann R, Romero C, Dall’Orso P, Cerisola A, Breuer T, et al.Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997-2005.Arch Dis Child. 2008;93(10):845-50. https://doi.org/10.1136/adc.2007.126243

  35. Baxter R, Ray P, Tran TN, Black S, Shinefield HR, Coplan PM, et al. Longtermeffectiveness of varicella vaccine: a 14-year, prospective cohort study.Pediatrics. 2013;131(5):e1389-96. https://doi.org/10.1542/peds.2012-3303

  36. Marin M, Marti M, Kambhampati A, Jeram SM, Seward JF.Global varicella vaccine effectiveness: A meta-analysis. Pediatrics.2016;137(3):e20153741. https://doi.org/10.1542/peds.2015-3741

  37. Anderson R, Kim S, Roberts N, Petrou S. Systematic review ofeconomic evaluations of varicella vaccination programmes. PLoS ONE.2023,18(3):e0282327. https://doi.org/10.1371/journal.pone.0282327

  38. Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O.Systematic review of models assessing the economic value of routinevaricella and herpes zoster vaccination in high-income countries. BMCPublic Health. 2015;15:533. https://doi.org/10.1186/s12889-015-1861-8

  39. Casabona G, Berton O, Singh T, Knuf M, Bonanni P. Combinedmeasles-mumps-rubella-varicella vaccine and febrile convulsions: the riskconsidered in the broad context. Exp Rev Vacc. 2023;22(1):764-76. https://doi.org/10.1080/14760584.2023.2252065

  40. Parikh R, Widenmaier R, Lecrenier N. A practitioner’s guideto the recombinant zoster vaccine: review of national vaccinationrecommendations. Exp Rev Vacc. 2021;20(9):1065-75. https://doi.org/10.1080/14760584.2021.1956906

  41. Zeevaert R, Thiry N, Maertens de Noordhout C, Roberfroid D.Efficacy and safety of the recombinant zoster vaccine: a systematic reviewand meta-analysis. Vaccine X. 2023;15:100397. https://doi.org/10.1016/j.jvacx.2023.100397




2020     |     www.medigraphic.com